

SUPPLEMENTARY MATERIAL

Table S1: Local and systemic adverse events reported at days 14, 28 and 45 after first BNT162b2 dose in 126 SLE patients

Adverse event	Day 14	Day 28	Day 42
Any adverse event	97 (77.0%)	46 (36.5%)	70 (56.5%)
Pain at injection site	85 (67.5%)	17 (13.5%)	49 (39.5%)
Fatigue	50 (39.7%)	26 (20.6%)	44 (35.5%)
Headache	32 (25.4%)	22 (17.5%)	23 (18.5%)
Fever	10 (7.9%)	3 (2.4%)	7 (5.6%)
Local redness	5 (4.0%)	1 (0.8%)	2 (1.6%)
Vomiting	8 (6.3%)	6 (4.8%)	6 (4.8%)
Diarrhea	13 (10.3%)	11 (8.7%)	9 (7.3%)
Muscle pain	19 (15.1%)	11 (8.7%)	17 (13.7%)
Joint pain	22 (17.5%)	11 (8.7%)	17 (13.7%)
Insomnia	17 (13.5%)	11 (8.7%)	10 (8.1%)

Variables are presented as n (%)

Table S2. Baseline predictors of day 42 anti-SARS-CoV-2 RBD IgG titers according to linear regression model. SLE activity is measured with SLEDAI.

	β	95% CI	p-value
Age, years	-0.47	-1.8, 0.88	0.5
Male sex	-55	-121, 10	0.10
SLEDAI 2K >4 on day 1	-19	-81, 42	0.5
C3, g/L	43	-70, 156	0.4
dsDNA antibodies, IU/mL	0.04	-0.05, 0.14	0.4
IFN	-2.9	-6.9, 1.1	0.2
IgA, g/L	0.62	-14, 15	>0.9
IgG, g/L	2.0	0.35, 3.6	0.018
IgM, g/L	12	-0.66, 25	0.063
Lymphocytes, day 1 (G/L)	9.0	-29, 47	0.6
Corticosteroids low	-18	-64, 28	0.4
Corticosteroids high	-51	-130, 28	0.2
Hydroxychloroquine	-22	-80, 36	0.5
Azathioprine	-128	-256, -0.22	0.050
Belimumab	-15	-89, 58	0.7
Mycophenolate mofetil	-77	-154	0.008
Other immunosuppressor	63	-32, 157	0.2
Methotrexate	-120	-241	<0.001

β: see Material and methods; CI = Confidence Interval; dsDNA: double stranded DNA; IFN: Interferon; RBD: Receptor Binding Domain; SLEDAI: SLE Disease Activity Index

Table S3. Baseline B cell predictors of serum neutralizing activity at day 42 according to linear regression model

	β	95% CI	p-value
Age, years	-0.01	-0.02, 0.01	0.6
Male sex	-0.76	-1.7, 0.15	0.10
At least one BILAG score ≥ B	-1.2	-2.1, -0.27	0.011
C3, g/L	0.81	-0.71, 2.3	0.3
dsDNA antibodies, IU/mL	0.00	0.00, 0.00	0.7
Detectable IFN alpha	-0.06	-0.11, 0.00	0.046
Total serum IgA, g/L	-0.02	-0.22, 0.17	0.8
Total serum IgG, g/L	0.01	-0.01, 0.04	0.3
Total serum IgM, g/L	0.05	-0.12, 0.23	0.5
Corticosteroids ≤10mg/day	-0.04	-0.67, 0.59	>0.9
Corticosteroids >10mg/day	-0.07	-1.1, 1.0	>0.9
Hydroxychloroquine	-0.01	-0.83, 0.80	>0.9
Azathioprine	-1.4	-3.2, 0.30	0.10
Belimumab	0.26	-0.75, 1.3	0.6
Mycophenolate mofetil	-1.1	-1.9, -0.34	0.005
Methotrexate	-1.9	-2.7, -1.0	<0.001
Other immunosuppressor	0.26	-1.0, 1.6	0.7

β: see Material and methods; BILAG: British Isles Lupus Assessment Group; CI = Confidence Interval; dsDNA: double stranded DNA; IFN: Interferon;

Table S4: Results of linear regression model for baseline B cell subpopulations and serum neutralizing activity at day 42

	β*	95% CI	p-value
Corticosteroids ≤10mg/day	-0.18	-0.79, 0.43	0.6
Corticosteroids >10mg/day	-1.0	-2.1, 0.19	0.10
Hydroxychloroquine	0.05	-0.90, 1.0	>0.9
Azathioprine	-0.85	-2.8, 1.1	0.4
Belimumab	0.30	-1.1, 1.7	0.7
Mycophenolate mofetil	-1.6	-2.6, -0.69	0.001
Methotrexate	-1.4	-2.4, -0.39	0.007
Other immunosuppressor	1.3	-1.1, 3.7	0.3
Marginal zone B lymphocytes, Day 1 (%)	-0.01	-0.04, 0.02	0.5
Autoreactive B lymphocytes, Day 1 (%)	-0.01	-0.04, 0.03	0.7
Naive B lymphocytes, Day 1 (%)	0.04	0.01, 0.07	0.006
Double negative B lymphocytes, Day 1 (%)	-0.01	-0.08, 0.07	0.9
Memory B lymphocytes, Day 1 (%)	-0.02	-0.04, 0.00	0.10

β: see Material and methods; CI = Confidence Interval; *Log (D614G); Autoreactive B cells (CD21lowCD38low); Double Negative B cells (CD27-IgD-); Marginal Zone B cells (CD27+IgD+); Memory B cells (CD27+IgD-); Naïve B cells (CD27-IgD+). B cell subsets frequencies are measured in total B cells.

Figure S1: Analysis of peripheral B cell subsets phenotyping

Representative flow cytometry gating strategy for CD27+IgD- memory B cells (A), CD27+IgD+ Marginal Zone B cells (B), CD27-IgD- Double Negative B cells (C), CD27-IgD+ Naïve B cells (D), CD21lowCD38low B cells (E)

Figure S2: Local and systemic reactions reported throughout the vaccination schedule.